Evogene Licenses BMC128, a Microbiome-Based Cancer Therapeutic, to Shanghai Lishan Biopharmaceuticals (EVGN.O)

[Para 1: The Lead] Evogene Ltd. (EVGN.O) has licensed its microbiome-based cancer therapeutic, BMC128, to Shanghai Lishan Biopharmaceuticals, a leading biopharma in China. The deal, announced on February 4, 2026, marks a significant step for Evogene in expanding its pipeline into the Asian market. BMC128 is designed to modulate the gut microbiome to enhance cancer immunotherapy responses. [Para 2-3: Supporting details & Context] Under the agreement, Shanghai Lishan Biopharmaceuticals will handle the development and commercialization of BMC128 in China. Financial terms of the deal were not disclosed. Evogene retains global rights to BMC128 except in China. The licensing deal is expected to boost Evogene's revenue and strengthen its position in the global biopharma sector. Recent clinical trials have shown promising results, with BMC128 demonstrating enhanced efficacy in combination with checkpoint inhibitors.